# Celldex Therapeutics (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/celldex-therapeutics-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 65.3 |
| Citations | 60,922 |
| City | Hampton |
| Country | US |
| Description | Celldex Therapeutics (United States) is a research organisation in Hampton, US. OpenAlex records 449 works and 60,922 citations for it. 286 researchers list it as their most recent affiliation. |
| Homepage | https://celldex.com |
| OpenAlex ID | https://openalex.org/I4210155447 |
| Region | New Jersey |
| Researchers | 286 |
| ROR ID | https://ror.org/055923009 |
| Type | company |
| Works | 449 |

## University papers

- [Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer/)
- [Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/anaplastic-lymphoma-kinase-inhibition-in-non-small-cell-lung-cancer/)
- [Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints](https://scholariq.org/papers/adaptive-resistance-to-therapeutic-pd-1-blockade-is-associated-with-upregulation/)
- [Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study](https://scholariq.org/papers/activity-and-safety-of-crizotinib-in-patients-with-alk-positive-non-small-cell/)
- [Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/overall-survival-and-long-term-safety-of-nivolumab-anti-programmed-death-1/)
- [PKC-θ is required for TCR-induced NF-κB activation in mature but not immature T lymphocytes](https://scholariq.org/papers/pkc-is-required-for-tcr-induced-nf-b-activation-in-mature-but-not-immature-t/)
- [Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors](https://scholariq.org/papers/efficacy-and-safety-of-abemaciclib-an-inhibitor-of-cdk4-and-cdk6-for-patients/)
- [Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study](https://scholariq.org/papers/safety-and-activity-of-alectinib-against-systemic-disease-and-brain-metastases/)
- [Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial](https://scholariq.org/papers/alectinib-in-alk-positive-crizotinib-resistant-non-small-cell-lung-cancer-a/)
- [Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine](https://scholariq.org/papers/whole-exome-sequencing-and-clinical-interpretation-of-formalin-fixed-paraffin/)
- [Cancer and Inflammation: Promise for Biologic Therapy](https://scholariq.org/papers/cancer-and-inflammation-promise-for-biologic-therapy/)
- [Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With <i>ALK</i> -Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pooled-analysis-of-cns-response-to-alectinib-in-two-studies-of-pretreated/)

## University top topics

Showing 8 of 25.

- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [T-cell and B-cell Immunology](https://scholariq.org/topics/t-cell-and-b-cell-immunology/)
- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.